PURPOSE
Rilvegostomig, an anti-PD-1/TIGIT bispecific antibody, was evaluated in this first-in-human, multicenter, phase I/II, open-label study (NCT04995523) in checkpoint inhibitor (CPI)-experienced patients with programmed death ligand-1 (PD-L1)-positive advanced or metastatic non-small-cell lung cancer (NSCLC).
PAT...
K. Rohrberg, M. Brandão, Eduardo Castañón Álvarez et al.· Clinical Cancer Research· 1 citation
INTRODUCTION
In patients treated with lorlatinib after failure of a second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), ALK mutations were identified as a potential marker of response. To identify other correlates, we evaluated ALK fusion subtypes and co-mutations to predict clinical out...
T. Bauer, J. Martini, B. Besse et al.· Journal of Thoracic Oncology· 0 citations
Despite a decade in, immunotherapy (IO) treatment selection in non-small cell lung cancer (NSCLC) remains largely guided by subgroup analyses and imperfect programmed death ligand 1 (PD-L1) and clinical scores. To our knowledge, I3LUNG ( NCT05537922 ) is currently the largest international, real-world, multimodal, arti...
A. Prelaj, V. Mišković, Matteo Sacco et al.· Nature Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
